Amol K. Narang, MD

Amol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences at John Hopkins Medicine, discusses the unanswered questions that still need to be addressed to further expand the role of stereotactic body radiation therapy (SBRT) in gastrointestinal (GI) cancers. Pancreatic cancer, in particular, poses additional challenges compared with other GI cancers, Narang says.

Investigators question how SBRT fits in the treatment landscape with nonoperative therapies, such as transarterial chemoembolization (TACE). Narang says these 2 therapies may need to be compared, but there may also be rationale to combine both SBRT and TACE in some GI cancers.

Videos

Amol K. Narang, MD, discusses the unanswered questions that still need to be addressed to further expand the role of stereotactic body radiation therapy in gastrointestinal cancers.

Unanswered Questions Remain Regarding SBRT in Gastrointestinal Cancers

Amol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences, John Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the improvement in systemic therapy for the treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.

In 2 landmark studies, the combination of FOLFIRINOX [folinic acid, fluorouracil (5-FU), irinotecan, and oxaliplatin] with gemcitabine and paclitaxel has shown significant improvement over the standard of care, gemcitabine alone.

Amol K. Narang, MD, discusses the improvement in systemic therapy for treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.

Amol K. Narang, MD | Authors

Articles

Unanswered Questions Remain Regarding SBRT in Gastrointestinal Cancers

Rationale for Locally Aggressive Treatment of Pancreatic Cancer